Gilead Sciences gets Veklury FDA approval for non-hospitalized Covid-19 patients
Gilead Sciences has secured expedited approval from the US Food and Drug Administration (FDA) for its nucleotide analog Veklury (remdesivir) for the treatment of non-hospitalized patients at high risk for Covid-19 disease progression. The Covid-19 drug has been indicated for adults and adolescents. Veklury has been the antiviral standard of care for the treatment of […]